Anika Therapeutics, Inc. (ANIK) stock
ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$12.85−0.07 (-0.54%)
Close on Nov 17, 2026Market cap $171.97MP/E –Yield –
Anika Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Anika Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $27.45M, up 10.6% year over year. For fiscal 2025 it was $25.77M, up 0.9% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $27.33M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.77M | +0.9% |
| FY2024 | Dec 31, 2024 | $25.54M | +17.4% |
| FY2023 | Dec 31, 2023 | $21.76M | +18.8% |
| FY2022 | Dec 31, 2022 | $18.32M | -33.0% |
| FY2021 | Dec 31, 2021 | $27.33M | +16.6% |
| FY2020 | Dec 31, 2020 | $23.43M | +40.6% |
| FY2019 | Dec 31, 2019 | $16.67M | -8.4% |
| FY2018 | Dec 31, 2018 | $18.19M | -3.2% |
| FY2017 | Dec 31, 2017 | $18.79M | +75.1% |
| FY2016 | Dec 31, 2016 | $10.73M | +19.4% |
| FY2015 | Dec 31, 2015 | $8.99M | +10.4% |
| FY2014 | Dec 31, 2014 | $8.14M | +15.4% |
| FY2013 | Dec 31, 2013 | $7.06M | +31.0% |
| FY2012 | Dec 31, 2012 | $5.39M | -12.7% |
| FY2011 | Dec 31, 2011 | $6.17M | -10.3% |
| FY2010 | Dec 31, 2010 | $6.87M | -16.0% |
| FY2009 | Dec 31, 2009 | $8.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.34M | +16.3% |
| Q1 FY2026 | Mar 31, 2026 | $6.71M | +10.8% |
| Q4 FY2025 | Dec 31, 2025 | $6.45M | -0.8% |
| Q3 FY2025 | Sep 30, 2025 | $6.95M | +16.8% |
| Q2 FY2025 | Jun 30, 2025 | $6.31M | -5.5% |
| Q1 FY2025 | Mar 31, 2025 | $6.06M | -5.5% |
| Q4 FY2024 | Dec 31, 2024 | $6.51M | -14.2% |
| Q3 FY2024 | Sep 30, 2024 | $5.95M | -23.7% |
| Q2 FY2024 | Jun 30, 2024 | $6.68M | -25.0% |
| Q1 FY2024 | Mar 31, 2024 | $6.41M | -23.7% |
| Q4 FY2023 | Dec 31, 2023 | $7.59M | -2.1% |
| Q3 FY2023 | Sep 30, 2023 | $7.79M | +6.7% |
| Q2 FY2023 | Jun 30, 2023 | $8.91M | +27.8% |
| Q1 FY2023 | Mar 31, 2023 | $8.40M | +36.4% |
| Q4 FY2022 | Dec 31, 2022 | $7.75M | +29.2% |
| Q3 FY2022 | Sep 30, 2022 | $7.30M | -4.8% |
| Q2 FY2022 | Jun 30, 2022 | $6.98M | -4.4% |
| Q1 FY2022 | Mar 31, 2022 | $6.16M | -3.2% |
| Q4 FY2021 | Dec 31, 2021 | $6.00M | -21.4% |
| Q3 FY2021 | Sep 30, 2021 | $7.67M | +47.1% |
| Q2 FY2021 | Jun 30, 2021 | $7.29M | +60.9% |
| Q1 FY2021 | Mar 31, 2021 | $6.36M | +5.1% |
| Q4 FY2020 | Dec 31, 2020 | $7.63M | +86.9% |
| Q3 FY2020 | Sep 30, 2020 | $5.22M | +25.5% |
| Q2 FY2020 | Jun 30, 2020 | $4.53M | +8.8% |
| Q1 FY2020 | Mar 31, 2020 | $6.05M | +42.1% |
| Q4 FY2019 | Dec 31, 2019 | $4.08M | +0.5% |
| Q3 FY2019 | Sep 30, 2019 | $4.16M | -1.7% |
| Q2 FY2019 | Jun 30, 2019 | $4.17M | -12.0% |
| Q1 FY2019 | Mar 31, 2019 | $4.26M | -17.5% |
| Q4 FY2018 | Dec 31, 2018 | $4.06M | -4.7% |
| Q3 FY2018 | Sep 30, 2018 | $4.23M | -27.6% |
| Q2 FY2018 | Jun 30, 2018 | $4.73M | +6.4% |
| Q1 FY2018 | Mar 31, 2018 | $5.16M | +22.0% |
| Q4 FY2017 | Dec 31, 2017 | $4.27M | +44.2% |
| Q3 FY2017 | Sep 30, 2017 | $5.84M | +107.0% |
| Q2 FY2017 | Jun 30, 2017 | $4.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.23M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.96M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.82M | – |
See a number that looks wrong?